Related Articles
Pathotropic nanoparticles for cancer gene therapy Rexin-G™ IV: Three-year clinical experience
Le morte du tumour: Histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes
Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery
Rexin‑G®, a tumor‑targeted retrovector for malignant peripheral nerve sheath tumor: A case report
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors